In order to analyse the molecular signalling connected to inhibitor treatment, and starting from previous observation of ERK1/2 pathway activation in AD patients with mild to severe pathology, together with previous reports showing 37/67 kDa LR-dependent regulation of MAPK phosphatases activity, which controls ERK signalling [52], we analysed pERK levels in inhibitor-treated GT1 cells compared to untreated control cells. Here, MAPK3 is linked to Alzheimer disease.